XML 12 R2.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 72,549 $ 55,570
Short-term investments 215,776 253,374
Accounts receivable, net 39,677 19,947
Inventory 11,250 11,346
Other current assets 5,593 9,814
Total current assets 344,845 350,051
Property, plant and equipment, net 69,852 71,336
Goodwill 76,501 76,501
Other assets 681 754
Total assets 491,879 498,642
Current liabilities:    
Accounts payable 2,349 2,363
Accrued compensation 10,044 5,998
Accrued clinical trial expenses 10,596 8,220
Other accrued expenses 6,284 4,156
Interest payable 4,144 4,198
Capital lease obligations, current portion 4,782 4,756
Deferred revenue, current portion 17,240 21,428
Other current liabilities 10,506 10,127
Total current liabilities 65,945 61,246
Senior secured notes, net 242,130 241,699
Capital lease obligations, less current portion 3,325 1,073
Liability related to the sale of future royalties, net 114,631 116,029
Deferred revenue, less current portion 59,587 62,426
Other long-term liabilities 6,536 9,740
Total liabilities $ 492,154 $ 492,213
Commitments and contingencies
Stockholders’ equity (deficit):    
Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated, issued or outstanding at March 31, 2016 or December 31, 2015 $ 0 $ 0
Common stock, $0.0001 par value; 300,000 shares authorized; 136,151 shares and 135,289 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively 13 13
Capital in excess of par value 1,888,531 1,876,072
Accumulated other comprehensive loss (1,835) (2,170)
Accumulated deficit (1,886,984) (1,867,486)
Total stockholders’ equity (deficit) (275) 6,429
Total liabilities and stockholders’ equity (deficit) $ 491,879 $ 498,642